Members Advisory Group LLC Increases Stake in Pfizer Inc. $PFE

Members Advisory Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 2.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 212,296 shares of the biopharmaceutical company’s stock after purchasing an additional 5,351 shares during the period. Pfizer makes up 1.9% of Members Advisory Group LLC’s portfolio, making the stock its 17th largest holding. Members Advisory Group LLC’s holdings in Pfizer were worth $5,146,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Pfizer by 69.0% during the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 25,785 shares during the period. Appleton Partners Inc. MA grew its position in Pfizer by 18.6% in the 1st quarter. Appleton Partners Inc. MA now owns 11,416 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 1,789 shares during the last quarter. Finally, Nilsine Partners LLC increased its stake in Pfizer by 27.1% in the first quarter. Nilsine Partners LLC now owns 15,205 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 3,245 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

Shares of PFE opened at $24.52 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a 50 day moving average price of $24.89 and a 200-day moving average price of $24.11. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.36. The stock has a market capitalization of $139.38 billion, a PE ratio of 13.04, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.